Substrate
financeSourced

Cycurion Names New Director Following Officer Departure

Cycurion Inc. reported the election of a new board member and the departure of a principal officer in an 8-K filed with the SEC on June 2 2026. The change triggers updated disclosures on board composition and requires the company to file any related material agreements or compensation arrangements that follow standard Form 8-K Item 5.02 rules.

SEC EDGAR — Cycurion, Inc.
1 source·Jun 1, 8:00 PM·1m read
Cycurion Names New Director Following Officer Departureinvestorideas.com
Audio version
Tap play to generate a narrated version.

Cycurion Inc. (CIK 0001868419) disclosed the departure of a principal officer and the election of a new director in a Form 8-K submitted to the SEC on June 2 2026.

The filing covers Item 5.02 on departure and election of directors or principal officers, Item 7.01 on Regulation FD disclosure, and Item 9.01 on financial statements and exhibits. Per the SEC EDGAR record, the company identified the named individual, the specific role affected, whether the action constitutes a departure or election, the effective date, and any cited cause.

The operational delta replaces the prior officer or board configuration with the new one effective on the date stated in the filing. The company must now update its internal records, notify relevant regulators where required, and determine whether any separation payments, consulting agreements, or indemnification obligations trigger additional disclosures within the four-business-day window typical for Item 5.02 events.

Downstream, the change requires Cycurion to evaluate whether the departure or election creates any new related-party transactions that must be reported on a subsequent Form 8-K or incorporated into its next quarterly or annual report. The board composition update also affects quorum and committee assignments for any upcoming shareholder votes or corporate actions.

Standard SEC rules further require the company to attach any material definitive agreements connected to the departure as exhibits under Item 9.01.

This marks the latest board-level change for the non-watchlist public company. The filing stands as the primary record; no prior officer transition for this individual appears in the immediate preceding 8-K sequence referenced in the EDGAR metadata.

Coverage spread

Substrate’s article above is written from the primary record. Below: how mainstream outlets reported the same event.

No mainstream coverage of this story has surfaced yet.

Transparency

Confidence90%

Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.

Related Stories

U.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effectthehindu.com
finance46 min ago

U.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effect

A U.S. aircraft fired an AGM-114 Hellfire missile into the engine room of the M/T Lexie on Tuesday, disabling the unladen vessel as it headed toward Kharg Island. The strike followed repeated ignored warnings over 24 hours.

FI
FI
OS
BBC News
4 sources
Fed Chairman Names Two Outside Advisers During Transitionprnewswire.com
finance46 min ago

Fed Chairman Names Two Outside Advisers During Transition

Federal Reserve Chairman Kevin Warsh appointed two interim advisers shortly after taking the post. One previously contributed to a conservative plan calling for major changes at the central bank.

FI
Wall Street Journal
2 sources
Forte Biosciences Accepts Resignation of Director David Veitchinsidermonkey.com
finance2 hrs agoSourced

Forte Biosciences Accepts Resignation of Director David Veitch

Forte Biosciences disclosed the resignation of independent director David Veitch from its board effective June 1 2026. The departure reduces the company's board size and triggers standard SEC and Nasdaq disclosure obligations for director changes at the clinical-stage biopharmace…

SEC EDGAR — Forte Biosciences, Inc. (FBRX)
1 source